Neoton Phlebo (Phosphocreatine Sodium)

Phosphocreatine Sodium, the active ingredient in Neoton Phlebo, is a metabolic agent presented as an intravenous solution for injection use. It is employed to support myocardial energy metabolism during ischemic events and cardiac procedures.

GNH USA supplies Neoton Phlebo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Neoton Phlebo is used in clinical settings that involve myocardial energy compromise and cardiac surgery. - Acute myocardial ischemia: helps restore ATP levels in ischemic heart muscle. - Cardiac surgery (ischemia‑reperfusion): provides cardioprotection during cardiopulmonary bypass. - Heart failure exacerbations: supports myocardial energetics when oxygen supply is limited.

Neoton Phlebo may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion site pain or erythema - Transient hypotension - Nausea or vomiting - Headache - Flushing - Dizziness

Serious or Rare Side Effects: - Severe hypotension or cardiovascular collapse - Cardiac arrhythmias - Anaphylactic or severe allergic reaction - Cardiac arrest - Pulmonary edema - Thrombophlebitis at the infusion site

Neoton Phlebo should be administered under close medical supervision with attention to patient‑specific factors. - Renal impairment: adjust infusion rate and monitor renal function. - Hepatic dysfunction: use cautiously, observe liver enzymes. - Electrolyte imbalance: correct potassium or calcium disturbances before infusion. - Cardiac monitoring: continuous ECG and blood pressure monitoring during administration. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may modify the safety or efficacy of Neoton Phlebo.

Major Interactions (Avoid): - Concurrent use with other high‑dose phosphate donors or creatine derivatives: risk of metabolic overload. - Strong vasodilators (e.g., nitroprusside) combined with rapid infusion: may precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt compensatory heart rate response. - Calcium channel blockers: monitor for additive negative inotropic effects. - Diuretics: watch electrolyte shifts, especially potassium. - Anticoagulants: observe for bleeding if infusion causes vascular irritation.